Alnylam Pharmaceuticals
ALNY
NASDAQ
IPO2004
about ALNY
Alnylam Pharmaceuticals is a biopharmaceutical company focused on developing innovative treatments using RNA interference (RNAi) technology to target and silence specific genes, aiming to address a wide range of diseases by reducing the production of harmful proteins in the body.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $319.00 | $319.50 | $309.92 | $41.6B | 829.28K |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| +$1.91 | n/a | n/a | 29.46% | 20.10% | 0% |